Elaiophylin, a novel autophagy inhibitor, exerts antitumor activity as a single agent in ovarian cancer cells
Xuejiao Zhao(Cancer Research Center), Ding Ma(Fudan University Shanghai Cancer Center), Qinglei Gao(Tongji Hospital), Jianfeng Zhou(Tongji Hospital), Peng Wu(China Medical University), Yang Yang(Affiliated Hospital of Hebei University), Hua Zhang(Jiangxi University of Traditional Chinese Medicine), Ting Wang(Xijing Hospital), Meng Li(Cancer Research Center), Zhihui Zheng(China National Pharmaceutical Group Corporation (China)), Qin Yu(Cancer Research Center), Xinhua Lu(Renji Hospital), Dao Wen Wang(Tongji Hospital), Yong Fang(Tongji Hospital), Hui‐Ling Lai(Sun Yat-sen University)
Cited by 143
Related Papers
Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 Trial
|Journal of Thoracic Oncology|2021|311
Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China
|Journal of Hematology & Oncology|2017|256
Music improves sleep quality in older adults
|Journal of Advanced Nursing|2005|248
Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial
|The Lancet Haematology|2019|248
Technological advances in cancer immunity: from immunogenomics to single-cell analysis and artificial intelligence
|Signal Transduction and Targeted Therapy|2021|171